Wegener's granulomatosis: current and upcoming therapies by Langford, Carol A
180
ANCA = antineutrophil cytoplasmic antibodies; AZA = azathioprine; CSA = cyclosporine; CYC = cyclophosphamide; Fc = crystallizabe fragment;
IFN = interferon; IL = interleukin; IVIg = intravenous immunoglobulin; MMF = mycophenolate mofetil; MPA = microscopic polyangiitis; MPO =
myeloperoxidase; MTX = methotrexate; T/S = trimethoprim/sulfamethoxazole; Th1 = T helper cell type 1; TNF = tumor necrosis factor; WG =
Wegener’s granulomatosis.
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Introduction
Wegener’s granulomatosis (WG) is a unique clinicopatho-
logical disease entity characterized by necrotizing granulo-
matous vasculitis of the upper and lower respiratory tract,
pauci-immune segmental necrotizing glomerulonephritis,
and small vessel vasculitis. Because of its wide range of
manifestations, WG has a broad spectrum of severity that
includes the potential for alveolar hemorrhage or rapidly
progressive glomerulonephritis, which are immediately life
threatening.
It has long been appreciated that the immune system
plays a critical role in the pathogenesis of WG. Among the
earliest supportive evidence was the effectiveness of
cyclophosphamide (CYC) and prednisone, a potent
immunosuppressive regimen, to bring about clinical
improvement. This interrelationship between pathophysiol-
ogy and treatment has continued to deepen, as findings
from the laboratory prompt investigation of an expanding
range of immunologically selective agents.
The present article will focus on the treatment of WG,
examining the challenges that are faced in the exploration
of new therapies, the available data published in peer-
reviewed literature on individual regimens, and the general
approach to treatment.
Challenges in therapeutic investigations for
WG
The therapeutic goals in WG have expanded dramatically
over the past 30 years (Table 1). Prolongation of patient
survival was the primary objective prior to the 1970s as
82% of patients with active WG died within 1 year [1].
Long-term survival became possible with the introduction
of prednisone and CYC [2], although morbidity and mor-
tality continued to occur as a result of treatment-induced
toxicity and disease relapse. This prompted the search for
safer treatment options that reduce disease recurrence.
The opportunity to explore new therapies in WG has,
however, brought challenges in clinical trial design
(Table 2).
Outcome measures play an important role in the evalua-
tion of treatment efficacy in WG. Remission and relapse
are the most frequently used outcome terms, which are
based on disease activity. There remains no unequivocally
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reliable means by which to confirm active disease, and
assessment is based on clinical parameters from physical
examination, from the laboratory, and from radiographic
studies. The difficulty of determining disease activity is
further compounded in multicenter trials, as definitions
may not be universal between investigators. A significant
area of progress in the conduct of clinical trials for WG
has been the recognized necessity of having predefined
outcome measures and their definition in the published
methods. As a means of standardizing the assessment of
disease activity, the development and validation of instru-
ments has been actively sought [3]. This work under-
scores the importance for definition of outcome measures
in all studies of new therapeutic agents.
Clinical trial design in WG is influenced by the effective-
ness of available therapies. This is most importantly due to
the potential for active WG to be a life-threatening disease.
Study design must address the patient population to be
enrolled, the patients’ severity of disease, and how stan-
dard therapies impact the regimen being examined.
Current treatment approaches also influence sample size
estimates and the length of follow-up. As CYC and pred-
nisone induce remission of active WG in 75–100% of
patients [4–6], approximately 200 patients per arm would
be required to test a comparative agent of remission induc-
tion. Use of sustained remission as a primary outcome
measure similarly presents a challenge to following induc-
tion treatment with CYC and glucocorticoids, as 80–83%
of patients remain in remission at 18 months [6,7].
Conducting therapeutic studies in WG is additionally
complicated by the disease rarity. Based upon an analysis
using the National Hospital Discharge Survey, the
1986–1990 United States prevalence of WG was esti-
mated to be three per 100,000 persons [8]. While there
remains an important role for rigorous standardized, early-
phase, open-label studies, randomized, multicenter trials
are being pursued to further address comparative issues
of efficacy.
Therapeutic data in WG
When evaluating any therapeutic publication in WG, the
study methods must be judiciously examined (Table 3).
The peer-reviewed literature to date contains very few suf-
ficiently powered randomized trials in WG, with retrospec-
tive series and case reports forming a substantial
proportion of the published therapeutic literature. Most of
the data on which current treatment is based comes from
prospective standardized, open-label trials.
In the following sections, the data for therapeutic agents
used in WG and their immunologic effects will be
reviewed. The pathogenetic mechanisms through which
the currently utilized treatments act in WG remain unclear.
With the exception of the selective immunomodulatory
agents that are being explored investigationally, each of
these therapies has broad effects on the immune
response. While this has probably been instrumental in
the efficacy of these agents, it is also frequently responsi-
ble for their observed toxicities.
Glucocorticoids
Prior to the time when treatment became available, active
WG was a rapidly fatal disease in which patients survived
a median of 5 months [1]. Glucocorticoids were the first
applied therapy and, while some patients transiently
improved, the median survival time remained only
12.5 months [9]. In a National Institutes of Health cohort,
96% of patients who had been treated with glucocorti-
coids alone prior to referral had progressive disease [10].
Of the 45 patients with renal involvement, none experi-
enced sustained improvement with glucocorticoid
monotherapy. These data support glucocorticoids alone
being insufficient therapy for active WG affecting a major
organ, and for glomerulonephritis in particular.
Cyclophosphamide
The immunosuppressive properties of cytotoxic agents
became appreciated during the 1950s and 1960s.
Emerging in concert with these findings was evidence that
Table 1
Goals of treatment for Wegener’s granulomatosis
Patient survival
Induce remission of active disease
Reduce disease relapse
Minimize therapeutic toxicity
Use the least toxic yet effective treatment option
Actively pursue strategies to prevent and monitor for toxicity
Use treatment regimens at doses and schedules on which there 
are rigorous published data
Table 2
Challenges in conducting therapeutic trials in Wegener’s
granulomatosis
Rarity of Wegener’s granulomatosis
Potential for active disease to be life threatening
Available treatment of established efficacy
Definition of outcome measures
Imprecise means of assessing active disease
Extended follow-up is necessary to fully assess relapse and to reach
study endpoints182
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immunologic mechanisms played an important role in the
pathophysiology of WG. Based upon these observations,
case reports began to appear on the use of cytotoxic
agents in WG. The efficacy of these approaches remained
uncertain until 1973, when Fauci and Wolff explored the
immunologic and clinical effects of CYC and glucocorti-
coids in WG [2].
CYC is an alkylating agent that results in cross-linking of
DNA, in decreased DNA synthesis, and in apoptosis. The
actions of CYC also impact on a number of components
of the immune response including decreasing the number
of both T lymphocytes and B lymphocytes, reducing lym-
phocyte proliferation, decreasing antibody production,
suppressing delayed hypersensitivity to new antigens, and
interfering with the function of both resting and stimulated
B lymphocytes.
In the regimen studied by Fauci and Wolff, 2 mg/kg/day
CYC is given together with 1 mg/kg/day prednisone [11].
At the end of 1 month, if there is evidence of improvement,
the prednisone is tapered to an alternate day schedule over
3 months and discontinued by 6–9 months. CYC is main-
tained for 1 year past remission, after which time it is
tapered and discontinued. Of 133 patients who were
treated with daily CYC and prednisone at the National
Institutes of Health over a 24-year span, 91% had a
marked improvement in their disease, 75% achieved a
complete remission, and an 80% survival rate was seen
[4]. Reinhold-Keller and colleagues similarly observed a
median survival of 21.7 years in their series of 155 patients,
92% of whom received CYC and prednisone [12].
Despite the efficacy of daily CYC and prednisone to
induce remission, 50% of patients in the National Institutes
of Health series later went on to relapse, and 42% experi-
enced serious morbidity from the side effects of treatment
[4]. CYC has significant toxicities including bone marrow
suppression, infection, infertility, myelodysplasia, and
bladder injury. Talar-Williams and colleagues reported that,
of 145 WG patients treated with daily CYC, 6% developed
transitional cell carcinoma of the bladder, which by
Kaplan–Meier estimates may rise to 16% 15 years follow-
ing the first exposure to CYC [13]. While extended analy-
ses have therefore confirmed the ability of CYC and
glucocorticoids to prolong patient survival in WG, they also
supported the exploration of further treatment options.
Intermittent CYC
Interest in the use of intermittent CYC in WG was encour-
aged by its successful application in systemic lupus ery-
thematosus. Reduction of toxicity also motivated the use
of intermittent CYC, although it remains unclear whether
the risk of myelodysplasia, infertility, or bladder cancer is
influenced by the frequency of administration or the cumu-
lative CYC dose.
Table 3
Points to evaluate in assessing a Wegener’s granulomatosis therapeutic study
Type and design of study Retrospective, prospective, open-label, randomized
Single center or multicenter
Study size For open-label trials, how many patients were included?
For randomized trials, were the sample size per arm and power sufficient to draw conclusions?
Patient population Did the study enroll patients with other forms of vasculitis?
How was Wegener’s granulomatosis diagnosed?
Were patients enrolled at initial diagnosis or relapse?
Site of organ involvement What was the distribution of organ involvement?
Were there any patients who had disease isolated to nonmajor organ sites such as the skin, the joint, or the sinus?
Were patients enrolled for sites known to be of limited medical responsiveness (i.e. subglottic stenosis)?
Were methods in place to rule out other processes that could have the appearance of active disease?
Definition of outcome measures How did the study define active disease, remission, and relapse?
Were outcome measures clearly defined in the methods?
Concurrent therapies Were immunosuppressive therapies used concurrently with the agent or regimen being studied?
Standardization Did all enrolled patients receive a standarized dose and duration of the study agent?
Was the glucocorticoid dose and taper standardized?
At what point in time did patients enter the study (i.e. at beginning of induction or at remission)?
Study duration What was the median follow-up time?
Were patients followed for sufficient duration to observe relapses?183
The utility of intermittent administration in WG has
remained controversial. Much of the literature in which effi-
cacy has been concluded has come from retrospective
nonstandardized series and from prospective inception
cohort studies [14]. Prospective standardized data involv-
ing more than 10 patients are available from two nonran-
domized studies and from three randomized trials. In one
open-label prospective study of 14 patients, 93% had
initial improvement and 50% achieved remission, but only
21% had a sustained remission [15]. In another open-
label series of 43 patients, 42% sustained a partial or
complete remission for 6 months after discontinuation of
intermittent CYC [16].
In examining the three randomized trials that compared
intermittent CYC with daily CYC, two of them included
patients with microscopic polyangiitis (MPA) or polyarteri-
tis nodosa and the maximum enrollment was 30 patients
per arm [5,17,18]. None of these trials therefore had suffi-
cient power to draw conclusions of equivalence. In exam-
ining the results, the two trials found no difference in the
rate of survival, remission, or relapse between intermittent
CYC and daily CYC. In the one randomized trial that
enrolled only patients with WG, a similar rate of remission
was seen in both groups, but the relapse rate in the inter-
mittent CYC group was 52% as compared with 18% in
those who received daily CYC [5].
de Groot and colleagues performed a detailed examina-
tion of the literature where intermittent CYC had been
used in the treatment of WG [19]. The tables in their
paper illustrate the wide range of CYC doses and admin-
istration frequency, concurrent therapies, and vasculitic
diseases that have been encompassed by past publica-
tions. These authors performed a meta-analysis of the
three randomized trials, which suggested that, compared
with daily CYC, intermittent CYC was less likely to fail to
induce remission and was less toxic, but was associated
with a higher relapse rate. However, the diverse designs in
the individual trials confound the ability to draw any con-
clusions from their collective analysis.
Data from the available prospective standardized studies
suggest that intermittent CYC in WG is associated with a
high frequency of relapse. Although some authors believe
intermittent CYC and daily CYC to be of equal efficacy to
induce remission, this remains unproven by a sufficiently
powered trial.
Staged regimens for induction and remission
maintenance
With the goal of reducing toxicity, recent studies have
examined the use of staged regimens whereby the use of
CYC is confined to the period of time needed to induce
remission, after which time CYC is stopped and remission
is maintained with a less toxic medication. Methotrexate
(MTX) and azathioprine (AZA) have been evaluated for
remission maintenance.
Langford and colleagues conducted a prospective stan-
dardized, open-label trial in which 42 patients with active
WG received 2 mg/kg/day CYC and 1 mg/kg/day pred-
nisone to induce disease remission, followed by
20–25 mg/week MTX for remission maintenance [6,20].
Patient survival was 98%, with one death occurring from a
myocardial infarction not related to vasculitis. Remission
was achieved in 100% of patients at a median time of
3 months, which represented the duration of CYC expo-
sure. Twenty-two patients (52%) relapsed, with glomeru-
lonephritis occurring in 16 patients. Serum creatinine
increased by ≥0.2 mg/dl in four patients (maximum eleva-
tion, 0.4 mg/dl) but returned to baseline with treatment.
Two patients (5%) had to withdraw from the study as a
result of MTX pneumonitis.
In another study, Reinhold-Keller and colleagues treated
71 patients with intravenous 0.3 mg/kg/week MTX after
complete or partial remission was induced with daily CYC
[21]. The mean duration of CYC was 13.8 months (range,
1–66 months). Seventy patients received glucocorticoids
for remission induction and 55 remained on this therapy at
the start of the study. Of the 26 relapses (37%) 16 had
glomerulonephritis, with 14 patients exhibiting a rise in
serum creatinine to 1.5–2.0 mg/dl. One patient relapsed
with rapidly progressive glomerulonephritis and pulmonary
hemorrhage that was fatal. Leukopenia prompted with-
drawal of MTX in two patients and dosage reduction in an
additional seven patients, but there were no occurrences
of pneumonitis or serious infection.
In contrasting the two open-label studies, both found MTX
to be a well-tolerated therapy for the maintenance of
remission in WG, but they varied in the severity of renal
relapse. The reason for such divergent findings is unclear,
although differences in study design were present. Given
the potential for glomerulonephritis to be asymptomatic
and rapidly progressive, close renal surveillance is impor-
tant, regardless of the treatment regimen.
AZA has also been evaluated for remission maintenance.
Initial reports from open-label series suggested that AZA
may be able to maintain remission following induction with
daily CYC [11]. The European Vasculitis Study Group con-
ducted a randomized trial investigating CYC or AZA as a
remission therapy for vasculitis in patients with active gen-
eralized WG or MPA. Preliminary results from this trial have
been published in abstract and review publications [7]. All
patients in the European Vasculitis Study Group trial
received the same regimen of daily CYC and prednisolone
until remission (between 3 and 6 months), after which time
they were randomized to receive CYC or AZA. There was
no difference in relapse rate between the two arms at
Available online http://arthritis-research.com/content/5/4/180184
18 months. Adverse events were frequent, with a nonsignif-
icant trend to fewer severe, adverse events with AZA.
Methotrexate
Encouraging results from case reports as well as its
potential mechanisms of action prompted the investigation
of MTX as a therapeutic agent for WG. MTX inhibits dihy-
drofolate reductase and, at pharmacologic concentrations,
can increase adenosine accumulation and release from
cultured fibroblasts and endothelial cells [22]. (Adenosine
inhibits neutrophil adhesion to endothelial cells, inhibits
generation of toxic oxygen metabolites, inhibits production
of tumor necrosis factor [TNF], and may increase the
secretion of IL-10.)
The use of low-dose MTX and glucocorticoids to induce
remission has been studied in patients with active WG
who had nonimmediately life-threatening disease [23]. In a
prospective standardized, open-label trial, Sneller and col-
leagues treated 42 patients with 1 mg/kg/day prednisone
and 20–25 mg/week MTX [24]. Remission was induced in
33 of 42 patients (79%). Nineteen patients (58%) experi-
enced a relapse, 79% of which occurred when the MTX
dose was ≤15 mg/week [25]. The MTX and prednisone
regimen was ineffective at controlling disease activity in
only three (7%) patients, who then achieved remission
after treatment with daily CYC. Three fatalities occurred in
this study, two from Pneumocystis carinii pneumonia and
one from a pulmonary embolism. Three patients (7%) with-
drew because of MTX pneumonitis.
MTX is contraindicated in the setting of renal insufficiency,
which presents a limitation to its use in some patients with
WG. Even in the setting of normal renal function, some
physicians have expressed concern about using MTX in
patients with glomerulonephritis. In the trial by Sneller and
colleagues, although patients with poor renal function or
rapidly progressive renal failure were excluded, 50% had
active glomerulonephritis. The presence of glomeru-
lonephritis did not influence the likelihood of achieving
remission, the time to remission, or the duration of remis-
sion. An analysis of the long-term renal outcome of this
population found that, of the 20 patients who achieved
renal remission, two patients had a rise >0.2 mg/dl in their
serum creatinine, 12 patients had stable renal function,
and six patients had improvement in their serum creatinine
[26]. These findings suggest that the use of MTX to treat
selected patients with WG-associated glomerulonephritis
and a normal or near normal serum creatinine was not
associated with a long-term decline in renal function.
Two other studies have examined the use of MTX for the
induction of remission in WG. In a prospective open-label
study, de Groot and colleagues treated 17 patients with
intravenous 0.3 mg/kg/week MTX combined with pred-
nisone [27]. Ten patients (59%) achieved a complete or
partial remission, with the seven patients who did not
respond having received a median prednisone dose of
only 7.5 mg daily. Significant side effects, including oppor-
tunistic infections, did not occur. In a retrospective series
of 19 patients treated by Stone and colleagues, the com-
bination of MTX and 20–60 mg prednisone daily brought
about remission in 74% of patients [28]. Eight patients
(57%) relapsed while taking a mean MTX dose of
10.8 mg/week. Two patients discontinued MTX for ele-
vated liver enzymes, but there were no cases of oppor-
tunistic infection, pneumonitis, or cytopenia.
Azathioprine
The ability for AZA to be given to patients with renal insuf-
ficiency and the comparative safety compared with CYC
has made it an attractive immunosuppressive agent in
WG. AZA is a purine analog and a prodrug of 6-mercapto-
purine. Metabolites of AZA have been shown to inhibit
de novo synthesis of purine ribonucleotides, to inhibit
purine ribonucleotide interconversion, and to incorporate
into cellular DNA and RNA. Mechanisms through which
AZA may impact on immune function include suppression
of lymphocyte proliferation, suppression of natural killer
cell activity, inhibition of monocyte and antibody produc-
tion, and inhibition of cell-mediated and humoral immunity.
Limited data examining the use of AZA and prednisone
for induction of remission have not supported efficacy. In
one series, 10 of 11 patients with active WG treated with
AZA did not achieve remission and had progressive
organ dysfunction [11]. However, as discussed under
staged regimens, data from open-label and randomized
trials suggest that AZA can maintain remission after
induction with CYC [7].
Mycophenolate mofetil
Mycophenolate mofetil (MMF) is an ester prodrug of
mycophenolic acid, which is a noncompetitive and
reversible inhibitor of inosine monophosphate dehydroge-
nase. Inhibition of inosine monophosphate dehydrogenase
blocks the de novo synthesis of guanosine nucleotides,
which are necessary substrates for DNA and RNA synthe-
sis. Unlike other cell types, lymphocytes rely solely on the
de novo pathway for the generation of guanosine. In vitro,
MMF has been shown to inhibit proliferative responses of
T lymphocytes and B lymphocytes, to suppress antibody
formation by B lymphocytes, and to prevent the glycosyla-
tion of glycoproteins involved in intercellular adhesion of
leukocytes to endothelial cells. MMF has been success-
fully used in renal transplantation where randomized trials
have found MMF to be superior to AZA in reducing the
risk of acute rejection during the first 6 and 12 months fol-
lowing surgery.
Nowack and colleagues performed an open-label,
prospective standardized study to examine 1000 mg MMF
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twice per day in nine patients with WG and in two patients
with MPA following remission induction with daily CYC
[29]. Of the 11 patients, one WG patient (9%) relapsed in
the 14th month of maintenance therapy. Adverse events
included abdominal pain, diarrhea, respiratory infection,
leukopenia, and cytomegalovirus colitis. Although encour-
aging results have also been found in case reports, the
experience with this agent remains limited.
Other cytotoxic and immunosuppressive agents
The experience with other cytotoxic and immunosuppres-
sive agents in the treatment of WG comes solely from
case reports and small series. Interpretation of these find-
ings is often further confounded by the lack of outcome
measures and concurrent use of other therapies. For each
of these agents, there remain insufficient data to assess
efficacy, and they should be considered only where a con-
traindication to CYC, MTX, or AZA exists. The agents now
discussed include only those for which there has been
published experience in more than five patients.
Cyclosporin
Cyclosporin (CSA) is a calcineurin inhibitor that blocks the
transcription of IL-2 and other cytokines in activated T lym-
phocytes. A major drawback of CSA in WG is its potential
for nephrotoxicity and hypertension. Five patients in one
open-label, prospective trial were treated with
5 mg/kg/day CSA [30]. All five patients had stabilization
or improvement of their WG, but worsening occurred in
two patients upon dosage reduction to 3 mg/kg/day. In
another prospective open-label trial, 2 mg/kg CSA was
given to three patients with WG and to four patients with
MPA after remission had been achieved for 6 months with
prednisone and intermittent CYC or daily CYC [31]. No
patient developed a relapse during a mean follow-up
period of 24 months after the end of CYC treatment.
Deoxyspergualin
Deoxyspergualin is a synthetic analog of spergualin, a
product of Bacillus laterosporus that has immunosuppres-
sive properties. The mechanism of action of deoxysper-
gualin is unclear, although effects on B-cell differentiation
and T-lymphocyte maturation have been described. In a
prospective open-label study by Birck and colleagues,
deoxyspergualin was given to 20 patients with WG or
MPA who had resistance or contraindications to standard
therapy [32]. Leukopenia was an expected drug effect and
occurred in all patients. Mild to moderate infections were
observed, not associated with mortality or sepsis. Disease
improvement was said to occur in 70% of cases, although
outcome measures were not clearly defined.
Intravenous immunoglobulin
The investigation of intravenous immunoglobulin (IVIg) in
WG was prompted by the detection of anti-idiotype anti-
bodies to antineutrophil cytoplasmic antibodies (ANCA) in
IVIg preparations together with the proven efficacy of IVIg
in Kawasaki disease [33]. Three open-label studies and
one randomized trial have been published.
In one open-label study, IVIg was given alone or in combi-
nation with other therapies for 5 days [33,34]. Reduction
of disease activity occurred in 13 of the 14 patients (eight
patients with WG, five patients with MPA, and one patient
with rheumatoid vasculitis), with remission being achieved
in eight patients. In another open-label trial, 14 patients
with WG and one patient with ANCA-associated systemic
vasculitis were treated with IVIg over 5 days [35]. Six
patients experienced musculoskeletal, cutaneous, or oto-
laryngeal benefit from IVIg, but there was no improvement
of ophthalmic, pericardial, pulmonary, or renal manifesta-
tions, and no patient achieved complete remission. IVIg
alone has also been used to treat six patients with WG or
MPA without threatened vital organ involvement [36]. In
this open-label study, two patients had a partial response
but went on to require conventional treatment and four
patients entered remission, two of which later relapsed. In
the single randomized trial, 34 patients with active ANCA-
associated systemic vasculitis despite 2 months of pred-
nisone and CYC or AZA treatment received 0.4 g/kg/day
IVIg for 5 days or placebo [37], in addition to their previ-
ous immunosuppressive regimen. IVIg resulted in a statisti-
cally significant therapeutic response compared with
placebo, but this was not sustained beyond 3 months.
While these collective data are small and potentially con-
founded by the use of concomitant therapies, they do not
currently support the use of IVIg in the treatment of active
WG involving a major organ.
Trimethoprim/sulfamethoxazole
DeRemee and colleagues reported in 1985 that trimetho-
prim/sulfamethoxazole (T/S) brought improvement in 11 of
12 patients with WG [38]. Several investigators believe
that T/S is anti-inflammatory through interference with the
formation of oxygen-derived radicals by activated neu-
trophils. Other workers assert that the actions of T/S in
WG are related to antimicrobial effects. Mucosal damage
predisposes patients with WG to bacterial superinfection.
Staphylococcus aureus is the organism most frequently
cultured from the upper airways of patients with WG and
can be found in the absence of clinical infection [11,39].
From in vitro and in vivo studies, S. aureus can stimu-
late an immune response characterized by proliferation
of T lymphocytes and B lymphocytes, by secretion of
immunoglobulin, and by increased cytokine production
[40]. Investigation of S. aureus in WG remains ongoing,
but it is currently unclear whether this organism plays a
role in triggering or mediating disease pathophysiology.
T/S has been found in several reports to be beneficial in
treating WG limited to the upper and/or lower airways.
Interpretation of these results is confounded by their retro-
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spective nature, by the use of concurrent immunosuppres-
sive agents, by the difficulty in defining active upper
airways disease, and by the lack of controlling for infec-
tion. In one prospective series of nine patients in which
these factors were addressed, three patients improved but
failed to achieve remission while the remaining six patients
had disease progression [41]. In another prospective
study of 19 patients treated with T/S alone for disease
limited to the upper and/or lower airways, eight patients
(42%) had progression [42]. The role of T/S in the man-
agement of isolated upper airways disease remains incom-
pletely defined; however, T/S monotherapy should never
be used in the setting of glomerulonephritis or any other
severe disease manifestations.
T/S has also been studied for its ability to decrease
relapses. Stegeman and colleagues conducted a random-
ized, placebo, controlled trial in which 81 patients who
achieved remission with CYC and prednisone received
160 mg/800 mg T/S twice daily or placebo [43]. At
24 months, 82% of patients in the T/S group were in
remission as compared with 60% of the placebo group.
Only the recurrence of nasal or upper airway lesions was
significantly reduced, however, and no difference was
observed in relapses involving other organ systems. T/S
was discontinued in 20% of patients because of side
effects. Based upon these data, the use of T/S for relapse
prevention must be considered on an individual basis.
MTX-treated patients can safely receive 160 mg/800 mg
T/S three times a week to provide prophylaxis against
P. carinii, but twice-daily dosing should not be combined
with MTX as this may cause life-threatening bone marrow
suppression.
One of the most important roles for T/S in WG has been
as a prophylactic agent against P. carinii [24]. As this
infection carries a mortality rate of up to 35%, treatment
with T/S to provide prophylaxisis against P. carinii is rec-
ommended for all nonsulfa-allergic WG patients who are
receiving a cytotoxic agent combined with glucocorti-
coids.
Nonmedical treatment modalities
Subglottic stenosis occurs in about 20% of patients with
WG and is typically unresponsive to systemic immunosup-
pressive therapy. One approach that has been effective is
a surgical technique that combines mechanical dilation of
the trachea with the intratracheal injection of a long-acting
glucocorticoid. In one series of 20 patients treated with
intratracheal therapy, none required tracheostomy and six
patients with previous tracheostomies were decannulated
[44]. Patients who require immunosuppressive treatment
for other manifestations of WG should undergo this pro-
cedure concurrently. However, in the absence of major
organ disease activity, WG-related subglottic stenosis can
be optimally managed using this technique alone.
The role of plasmapheresis in the treatment of WG has
remained unclear. Plasmapheresis is most commonly con-
sidered in the setting of immediately life-threatening
disease; in particular, severe glomerulonephritis. The
hypothesis for its potential utility has included the removal
of inflammatory mediators and ANCA. Plasmapheresis has
not been specifically studied in WG, and the available
data from polyarteritis nodosa and pauci-immune crescen-
tic glomerulonephritis have not been of sufficient size to
resolve the question of its efficacy [45]. The use of
plasmapheresis remains actively investigated, but at this
time the unknown benefits must be weighed against the
risks of a large-bore vascular catheter and potential hemo-
dynamic instability.
Selective immunomodulatory agents
Monoclonal antibody and recombinant DNA technology
has lead to an expanding range of therapies capable of
directly targeting components of the immune response.
The evaluation of these agents in WG may provide both
new treatment options and insights into disease patho-
genesis. Although reports on the use of biologic agents in
WG have begun to appear in the literature, none of these
allow any conclusions to be drawn regarding their effi-
cacy. As biologic agents have the potential for unex-
pected toxicities and effects on disease, it is critical that
they be further investigated in WG prior to their use in
clinical practice.
Alemtuzumab
Alemtuzumab (CAMPATH-1H) is a humanized monoclonal
antibody directed against cell surface CD52 expressed on
normal and malignant B lymphocytes and T lymphocytes,
on natural killer cells, and on macrophages. Lockwood
and colleagues conducted a series of studies during the
1990s examining alemtuzumab, often with anti-CD4 in
selected patients with treatment-resistant systemic vas-
culitis [46]. The findings included both remissions as well
as side effects consisting of infusion reactions, infection,
autoimmune events, and prolonged lymphocyte depletion.
While these studies suggest the toxicity of alemtuzumab
to outweigh its benefits, they provided the first exploration
of a monoclonal antibody in WG.
TNF modulation: etanercept and infliximab
TNF modulatory agents have raised interest in the treat-
ment of WG because of the potential role of Th1
cytokines in this disease. Activated peripheral blood CD4+
T lymphocytes from patients with active WG have been
found to produce 10-fold to 20-fold higher levels of inter-
feron (IFN)-γ compared with healthy controls [47].
Increased production of TNF by activated CD4 T lympho-
cytes and of IL-12 by purified monocytes was also noted,
but production of IL-4, IL-5, and IL-10 from patients with
WG did not differ from controls. A Th1 pattern of cytokine
expression has also been exhibited by T-cell clones
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isolated  from WG nasal biopsy specimens displaying
granulomatous inflammation and, to a lesser extent, T-cell
clones and T-cell lines generated from bronchoalveolar
fluid [48]. Based on these observations, a hypothetic
pathogenic mechanism would be that patients with WG
have an immunoregulatory defect that, following exposure
to an infection and/or autoantigen, leads to an unbal-
anced production of Th1 cytokines with initiation and per-
petuation of the granulomatous vascular lesion that is
characteristic of WG.
Stone and colleagues treated 20 WG patients with etan-
ercept, a dimeric fusion protein consisting of the extracel-
lular ligand-binding portion of the human 75 kDa TNF
receptor linked to the Fc portion of human IgG1 [49].
Patients in this 6-month, open-label, phase I study
received 25 mg etanercept twice a week in combination
with standard therapies for WG. Etanercept was well tol-
erated with few adverse events, and concurrent treatment
with other immunosuppressive agents did not appear to
increase toxicity.
Three reports, each including less than 10 patients with
WG, have utilized infliximab, a chimeric IgG1 monoclonal
antibody that binds to TNF. Lamprecht and colleagues
examined the use of infliximab in six patients with refrac-
tory WG [50]. Patients received infliximab (3 mg/kg in two
patients and 5 mg/kg in four patients), with a 2-week inter-
val after the first administration and 4-week intervals
between infusions until remission, in addition to CYC and
glucocorticoids. Remission was induced in five patients
and glucocorticoid doses were tapered. No serious side
effects occurred, although one patient was withdrawn for
a suspected systemic infection.
Booth and colleagues described their experience with
200 mg infliximab given at monthly intervals for 3 months
in three patients with WG and in three patients with MPA
who had relapsing vasculitis [51]. Five patients had remis-
sion of their disease, with treatment allowing glucocorti-
coid withdrawal in three patients and reduction by more
than 50% in two patients. One patient experienced
fatigue, myalgia, and blurred vision 24 hours after the first
infusion, but infliximab was otherwise well tolerated.
Ten patients with refractory vasculitis (seven patients with
WG, two patients with rheumatoid vasculitis, and one
patient with cryoglobulinemic vasculitis) were treated by
Bartolucci and colleagues. The patients received 5 mg/kg
infliximab on days 1, 14, and 42, and then every 8 weeks
for 6 months [52]. Immunosuppressive agents were held
between days 0 and 42 in eight patients while glucocorti-
coids were maintained or decreased. Complete or partial
remission occurred in all patients. Infliximab was well toler-
ated, with two patients experiencing a transient cutaneous
eruption, one of which discontinued therapy.
B-lymphocyte depletion: rituximab
Specks and colleagues examined the use of rituximab, a
chimeric monoclonal antibody directed against the CD20
antigen found on the surface of normal and malignant B
lymphocytes, in a patient with relapsing PR3-ANCA-posi-
tive WG who had resistance or intolerance to standard
therapies [53]. In this case report, rituximab was used with
the hypothesis that elimination of pathogenic ANCA would
lead to the induction and maintenance of remission.
First described in 1982, ANCA are antibodies directed
against proteins in the primary granules of neutrophils and
in the lysosomes of monocytes [54]. More than 80% of
patients with typical active WG have detectable antibod-
ies to proteinase-3, a 29 kDa serine proteinase present in
neutrophil azurophilic granules. Antimyeloperoxidase
ANCA, which are more frequently seen in MPA, can occur
in 5–20% of patients with WG.
Although a number of in vitro observations have sug-
gested potential mechanisms whereby ANCA could con-
tribute to the pathogenesis of WG, the strongest evidence
has come from a recently described animal model. Xiao
and colleagues took myeloperoxidase (MPO) knockout
mice and immunized them with murine MPO [55,56].
Splenocytes from these mice or from control mice were
injected into recombinase-activating gene-2-deficient
mice. All mice developed glomerular immune deposits but
mice receiving anti-MPO splenocytes developed necrotiz-
ing and crescentic glomerulonephritis, granulomatous
inflammation, and systemic vasculitis. To test the patho-
genic potential of the antibodies alone, purified anti-MPO
IgG or control IgG was injected into recombinase-activat-
ing gene-2-deficient mice and into wild-type mice. Mice
that received anti-MPO IgG but not mice that received
control IgG developed a pauci-immune focal necrotizing
and crescentic glomerulonephritis. Although these data
support direct pathogenicity of ANCA in the mouse
model, there remain unanswered questions in human
disease. While this evidence would support the direct
pathogenicity of ANCA, the observation that patients with
high-titer ANCA can lack glomerulonephritis and may
remain in remission suggests that additional factors modu-
late disease occurrence in humans.
In the patient described by Specks and colleagues, ANCA
became negative by the end of the four weekly infusions of
375 mg/m2 rituximab, which was followed by evidence of
clinical improvement [53]. The ANCA titer started to
increase 9 months after treatment, which was preceded
by a return of CD19+ B cells. Although the patient
remained in remission, the decision was made to treat him
with a second course of rituximab. Following these infu-
sions, the patient’s ANCA persisted at high levels but the
disease remained in clinical remission. The persistence of
ANCA after the second course of rituximab in this patient
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and his continued remission raises new questions about
the role of ANCA and B lymphocytes in disease pathogen-
esis, about the origin of ANCA, and about the longevity of
plasma cells. Further therapeutic exploration of B-lympho-
cyte depletion together with the recent advances in the
mouse model may shed new insights into the role of
ANCA and humoral immunity in WG.
General therapeutic approach
With the expansion of therapeutic options in WG, physi-
cians will increasingly need to choose between different
treatment approaches in the care of their patients. In the
absence of direct comparative trials, decisions regarding a
management plan for an individual patient can be assisted
by considering several points, outlined in Table 4.
Glucocorticoids combined with CYC or MTX are the only
two regimens that have thus far been shown to induce
remission of active WG affecting a major organ. Patients
with alveolar hemorrhage, rapidly progressive glomeru-
lonephritis, central nervous system disease, or other mani-
festations that are immediately life threatening should
initially be treated with CYC and glucocorticoids. Once
remission has been induced, consideration can be given
to stopping CYC and beginning AZA or MTX treatment to
maintain remission. As there have been no randomized
trials comparing non-CYC maintenance agents, the choice
of maintenance therapy should be based on medication
contraindications and toxicity profiles, on the patient’s
relapse and disease history, and on physician experience
with each medication. In patients with active WG that is
not immediately life threatening, the decision whether to
use CYC or MTX for remission induction must again be
based on individual factors as there have been no head-to-
head assessments. Because of its potential toxicity, CYC
is rarely if ever justified for treating disease activity isolated
to the sinus, to the skin, or to the joint.
Monitoring and prevention of therapeutic toxicities play an
important role in overall patient management. This includes
pneumocystis prophylaxis as discussed earlier (see
Trimethoprim/sulfamethoxazole section), osteoporosis pre-
vention regimens with concurrent glucocorticoid treatment,
as well as medication-specific strategies (Table 5).
Conclusion
The therapeutic literature in WG has provided physicians
not only with current life-saving treatments, but also with
an important foundation for planning the future study of
new approaches. Although substantial progress has been
made, challenges remain in the search for regimens that
reduce disease relapse and therapeutic toxicity. Explo-
ration of the pathophysiology of WG together with the
development of targeted immunomodulatory agents may
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Table 4
Points to consider when deciding on a treatment regimen for a patient with active Wegener’s granulomatosis
Is the disease active? Differentiate active disease from:
Chronic sequelae of disease
Medication toxicity
Other diseases (in particular, infection)
How severe is the active disease? Immediately life-threatening disease necessitates initial treatment with 
cyclophosphamide and glucocorticoids
What organ sites are being affected? Certain sites of organ involvement, particularly subglottic stenosis, may not require or 
may not respond to systemic immunosuppressive therapy
What is the data on different therapeutic regimens? What is the data for the regimen being considered (see Table 3)?
Has the regimen improved survival?
What is the likelihood of inducing remission?
What is the relapse rate?
What are the known toxicities?
Consideration of individual patient factors History of medication toxicity
Contraindications to certain medications
Presence of previous organ damage
Relapse history with past treatment regimens
Age
Gender189
provide increasing treatment options. As new therapeutics
are introduced, careful study is essential in order to under-
stand their disease mechanisms and, more importantly,
their safety and efficacy in WG. Until such time when these
data become available, conventional immunosuppressive
agents will continue to provide an efficacious means of
inducing remission of active disease in patients with WG.
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